Answers are grounded in this paper and cite their sources.
A high proportion of COVID-19 patients had EBV reactivation that may be associated with an increased risk of death. Whether treatment with ganciclovir may decrease the mortality of COVID-19 patients complicated with EBV reactivation warrants to be addressed in a placebo-controlled randomized trial in the future.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: